Cara Therapeutics Management
Management criteria checks 3/4
Cara Therapeutics' CEO is Chris Posner, appointed in Nov 2021, has a tenure of 2.42 years. total yearly compensation is $2.51M, comprised of 27.9% salary and 72.1% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $74.53K. The average tenure of the management team and the board of directors is 2.3 years and 4.8 years respectively.
Key information
Chris Posner
Chief executive officer
US$2.5m
Total compensation
| CEO salary percentage | 27.9% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16
The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Jul 19It's Unlikely That The CEO Of Cara Therapeutics, Inc. (NASDAQ:CARA) Will See A Huge Pay Rise This Year
May 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$119m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$112m |
| Mar 31 2023 | n/a | n/a | -US$84m |
| Dec 31 2022 | US$3m | US$700k | -US$85m |
| Sep 30 2022 | n/a | n/a | -US$89m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$93m |
| Dec 31 2021 | US$10m | US$116k | -US$88m |
| Sep 30 2021 | n/a | n/a | US$24m |
| Jun 30 2021 | n/a | n/a | US$8m |
| Mar 31 2021 | n/a | n/a | US$14m |
| Dec 31 2020 | US$280k | n/a | US$8m |
| Sep 30 2020 | n/a | n/a | -US$99m |
| Jun 30 2020 | n/a | n/a | -US$115m |
| Mar 31 2020 | n/a | n/a | -US$113m |
| Dec 31 2019 | US$302k | n/a | -US$106m |
| Sep 30 2019 | n/a | n/a | -US$98m |
| Jun 30 2019 | n/a | n/a | -US$85m |
| Mar 31 2019 | n/a | n/a | -US$79m |
| Dec 31 2018 | US$494k | n/a | -US$74m |
Compensation vs Market: Chris's total compensation ($USD2.51M) is above average for companies of similar size in the US market ($USD667.11K).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Posner (53 yo)
2.4yrs
Tenure
US$2,509,979
Compensation
Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.4yrs | US$2.51m | 0.19% $ 74.5k | |
| Chief Financial Officer | 1.6yrs | US$2.21m | 0.015% $ 5.7k | |
| Co-Founder & Senior Advisor | 2.4yrs | US$10.20m | no data | |
| Chief Strategy Officer & Head of Investor Relations | 2.3yrs | no data | no data | |
| Chief Compliance Officer | 7.4yrs | US$1.59m | 0.15% $ 57.7k | |
| Senior Vice President of Regulatory Affairs & QA | 2.2yrs | no data | no data | |
| Manager of Investor Relations | no data | no data | no data |
2.3yrs
Average Tenure
56.5yo
Average Age
Experienced Management: CARA's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5.7yrs | US$2.51m | 0.19% $ 74.5k | |
| Independent Chairman & Lead Independent Director | 13.8yrs | US$614.87k | 0.082% $ 31.8k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9.8yrs | US$267.43k | 0.028% $ 10.9k | |
| Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 3.8yrs | US$257.43k | 0.028% $ 10.9k | |
| Independent Director | 1.4yrs | US$8.36k | 0% $ 0 |
4.8yrs
Average Tenure
60.5yo
Average Age
Experienced Board: CARA's board of directors are considered experienced (4.8 years average tenure).